Correvio'S Heart Drug Fails To Get Fda Approval
The U.S. Food And Drug Administration Has Declined To Approve Correvio Pharma Corp'S Drug To Correct Irregular Rhythm In The Upper Chambers Of The Heart, The Company Said On Tuesday.In The So-Called Complete Response Letter, The Fda Stated That While The Submitted Data Provides Substantial Evidence Of The Drug'S Effectiveness, The Data Does Not Provide Reassuring Evidence Of Brinavess' Safety, The Company Said.A Panel Of Independent Experts To The Fda Voted 11-2 Against Approving The Drug, Brinavess, Citing Serious Safety Risks, Including Low Blood Pressure And Irregular Rhythm In The Lower Heart Chambers During The Trials, Earlier This Month.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
